BLLN
BillionToOne, Inc.
September 22, 2026 · intraday
- Rarity
- 2.18
- Peak move
- +14.01%
- Float cap
- $2.0B
BillionToOne is a molecular diagnostics company that uses a single-molecule next-generation sequencing platform to detect and quantify genetic targets in cell-free DNA from a blood draw. It develops prenatal tests, including UNITY for fetal risk assessment, and oncology liquid biopsy tests, Northstar Select and Northstar Response, for therapy selection and treatment monitoring. Its tests are sold to physicians, clinics, and healthcare providers to guide patient care.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
4 events · 2 from SEC or newswire · 0 timed with the moveinsider_saleBillionToOne officer John Roderick ten Bosch filed notice to sell 1,416 Class A shares with a market value of $150,960 at an average price of $106.61 under a 10b5-1 plan dated September 21, 2026, with 9,917 shares sold for $1.1 million in the prior three months.
SEC144 0001959173-26-007058insider_saleBillionToOne SVP of Laboratory Operations John Roderick Ten Bosch sold 1,416 Class A shares at a weighted-average price of $97.54 for $138,116 on Sept. 9, 2026 under a Rule 10b5-1 plan adopted in June 2026, leaving a direct stake of about $2.4 million.
insider_saleBillionToOne General Counsel, Chief Compliance Officer and Secretary Thomas P. Lynch sold 35,112 Class A shares on Sept. 17, 2026 at prices around $110.29-$110.36 for about $3.87 million, alongside option exercises of 70,224 shares, cutting his direct stake about 98% to 700 shares.
insider_saleBillionToOne founder and CEO Oguzhan Atay disposed of 30,331 Class A shares at a weighted-average price of $99.91 for about $3 million on Sept. 14, 2026, representing 100% of his directly held equity stake.